Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Defective B-cell memory in patients with Down syndrome Ruud H.J. Verstegen, MD, Gertjan J. Driessen, MD, Sophinus J.W. Bartol, BSc, Carel J.M. van Noesel,

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events Keiichi Yamanaka, MD, PhD, Hitoshi.

Alveolar nitric oxide and asthma control in mild untreated asthma

Doina M. Racila, MD, Joel N. Kline, MD, MSc

Allergen immunotherapy: A practice parameter third update

Fatty acids, inflammation, and asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome Heleen D. de Koning, MD, Mariëlle E. van.

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study Karoline Krause, MD, Athanasios Tsianakas,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Dennis K. Ledford, MD, Sally Wenzel, MD

David A. Khan, MD Journal of Allergy and Clinical Immunology

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Allergic skin diseases

Sublingual immunotherapy for hazelnut food allergy: A randomized, double-blind, placebo-controlled study with a standardized hazelnut extract Ernesto.

Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

The National Biome Initiative: An allergy perspective

Treatment of chronic autoimmune urticaria with omalizumab

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma treatment and asthma prevention: A tale of 2 parallel pathways

René van Gent, MD, Cornelis K. van der Ent, MD, PhD, Maroeska M

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Reply Journal of Allergy and Clinical Immunology

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Christian Hennig, MD, Christine Happle, MD, Gesine Hansen, MD

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Aaron M. Drucker, MD, Paula J. Harvey, PhD

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

One step forward, 2 steps back: The enigma of preschool wheeze

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: A preclinical study Ousama Rachid, BPharm, MSc, Mutasem M.

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD,

TH9 immunodeficiency in patients with hyper-IgE syndrome

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

The Editors' Choice Journal of Allergy and Clinical Immunology

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Environmental factors and eosinophilic esophagitis

The GILL study: Glycerin-induced local reactions in immunotherapy

Advances in pediatric asthma in 2007

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Itching as a systemic disease

Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years Malgorzata Setkowicz, MD, PhD, Lucyna Mastalerz,

Presentation transcript:

Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W.M. van der Meer, MD, PhD, Anna Simon, MD, PhD Journal of Allergy and Clinical Immunology Volume 128, Issue 6, Pages 1352-1354 (December 2011) DOI: 10.1016/j.jaci.2011.05.023 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Rapid resolution of urticaria and arthritis on the first canakinumab injection. Pictures show urticarial rash in patients 1 and 2, arthritis of the left hand in patient 3 before canakinumab administration, and resolution of symptoms 4 days after injection. Journal of Allergy and Clinical Immunology 2011 128, 1352-1354DOI: (10.1016/j.jaci.2011.05.023) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Canakinumab treatment induces long-term suppression of systemic inflammation in patients with Schnitzler syndrome. C-reactive protein concentrations increased dramatically on cessation of anakinra and rapidly normalized after canakinumab administration (normal, <10 mg/L). Journal of Allergy and Clinical Immunology 2011 128, 1352-1354DOI: (10.1016/j.jaci.2011.05.023) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions